References
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, . Treatment of severe acute graftversus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
- Kraitchman DL, Tatsumi M, Gilson WD, Ishimori T, Kedziorek D, Walczak P, . Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation. 2005;112:1451–61.
- Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, . Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92–5.
- Shapira MY, Bloom AI, Or R, Sasson T, Nagler A, Resnick IB, . Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol. 2002;119:760–4.
- Nakai K, Tajima K, Tanigawa N, Matsumoto N, Zen K, Nomura S, . Intra-arterial steroid-injection therapy for steroid-refractory acute graft-versus-host disease with the evaluation of angiography. Bone Marrow Transplant. 2004; 33:1231–3.
- Kotobuki N, Hirose M, Takakura Y, Ohgushi H. Cultured autologous human cells for hard tissue regeneration: preparation and characterization of mesenchymal stem cells from bone marrow. Artif Organs. 2004;28:33–9.
- Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H. New bone Formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. J Pediatr. 2009;154;924–30.
- Kovacic JC, Graham RM. Stem-cell therapy for myocardial diseases. Lancet. 2004;363:1735–6.
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
- von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, . Treatment of refractory acute GvHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245–51.
- Ringden O, Le Blanc K. Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells. Biol Blood Marrow Transplant. 2006;12:693–94.
- Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933–46.